Drug Trial Radar · NCT05411588
A Study to Learn How the Study Medicine Called PF-07275315 Works in Healthy People
Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
65
Actual
Start
Jun 9, 2022
Primary completion
May 13, 2024
Study completion May 13, 2024
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Jun 9, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called PF-07275315) in healthy participants. This study is seeking participants who: * Are healthy as determined by medical evaluation. * Are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures. * Have a body mass index (BMI) of 17.5 to 32 kilogram per meter square - a total body weight of more than 50 kilograms (110 pounds) Participants will be divided randomly into 8 different groups. All participants will receive either one PF-07275315 or a harmless treatment that has no medical effect (placebo) intravenous (IV) infusion (given directly into a vein). Participants will take part in this study for up to 541 days. During this time, eligible participants will receive single increasing amounts of PF-07275315 or placebo. Increase will only occur if the sponsor agrees that the next dose is likely to have acceptable safety and tolerability. The follow-up visit will take place 271 days after first treatment.
Conditions
- Healthy Volunteers
Interventions
PF-07275315Drug
Active drug
PlaceboDrug
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with Adverse Events (AEs)Time frame: Baseline through study completion, approximately 561 days
- Number of participants with clinically meaningful change from baseline in laboratory Tests ResultsTime frame: Baseline through study completion, approximately 561 days
- Number of participants with clinically meaningful change from baseline in vital signsTime frame: Baseline through study completion, approximately 561 days
- Number of participants with Serious AEs (SAEs)Time frame: Baseline through study completion, approximately 561 days
- Number of participants with clinically meaningful change from baseline in ECG parametersTime frame: Baseline through study completion, approximately 561 days
Locations
5 sites in 2 countries. Site status is shown where the registry gives one.
Orange County Research Center
Lake Forest, California
Orange County Research Center
Tustin, California
New Haven Clinical Research Unit
New Haven, Connecticut
Qps-Mra, Llc
South Miami, Florida
Pfizer Clinical Research Unit - Brussels
Brussels, Bruxelles-capitale, Région de, Belgium
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.